In Reply
- PMID: 32604326
- DOI: 10.1097/GME.0000000000001607
In Reply
Comment on
-
MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence.Menopause. 2020 Jun;27(6):722-725. doi: 10.1097/GME.0000000000001516. Menopause. 2020. PMID: 32068684
-
To the Editor.Menopause. 2020 Jul;27(7):836-837. doi: 10.1097/GME.0000000000001606. Menopause. 2020. PMID: 32604325 No abstract available.
References
-
- Lukas VA, Simon JA. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence. Menopause 2020; 27:722–725.
-
- Reed SD, LaCroix AZ, Anderson GL, et al. Lights on MsFLASH: a review of contributions. Menopause 2020; 27:473–484.
-
- Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference p. genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21:1063–1068.
-
- Guidance for Industry Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommended Prescribing Information for Health Care Providers and Patient Labeling. In: OGD, ed. Silver Spring, MD: Food and Drug Administration; 2005.
-
- Guidance for Industry Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommendations for Clinical Evaluation. In: OGD, ed. Silver Spring, MD: Food and Drug Administration; 2003.
Publication types
LinkOut - more resources
Full Text Sources